The indications of pezopanib do not include early stage renal cancer, which is mainly treated by surgery. Early-stage renal cancer mostly refers to patients with stage I or II, at this time, the patients have not yet developed tumor metastasis, and it is expected to achieve clinical cure through radical surgery, so radical surgery is mostly recommended in the absence of obvious contraindications, and partial nephrectomy or radical nephrectomy can be chosen according to the specific conditions. Patients who cannot tolerate surgery can consider local embolization, stereotactic radiotherapy and ablation therapy. Pezopanib is a multi-targeted tyrosine kinase inhibitor, which is currently approved for the first-line treatment of patients with advanced renal cell carcinoma. It is also available for patients who have previously received cytokine therapy that has failed. Thus early stage renal cancer is not included in its indication. It is recommended that patients with early-stage renal cancer should go to the hospital as soon as possible and consult professional doctors to determine the scientific and reasonable treatment plan according to their conditions. Please strictly follow the doctor’s prescription for medication, do not use medication on your own.